Pesquisar
Collplant Biotechnologies Ltd
CLGNAdicionar à lista de desejos
3.750USD
-0.290-7.18%
Horário de mercado 09/24, 10:21（ET）
70.91MValor de mercado
PerdaP/L TTM
Sobre o Collplant Biotechnologies Ltd Empresa
CollPlant Biotechnologies Ltd, formerly known as Collplant Holdings Ltd, is a company dealing in aesthetic medicine and regenerative medicine based in Israel. The company provides products and technologies for broadly understood regenerative medicine, including tissue regeneration and organ production. The technology is based on plants and is based on the production of collagen type I (rhCollagen).
Collplant Biotechnologies Ltd Perfil
Código da empresaCLGN
Nome da EmpresaCollplant Biotechnologies Ltd
Data de listagemSep 01, 1993
CEORotem (Eran)
Número de funcionários57
Tipo de títulosOrdinary Share
Fim do ano fiscalSep 01
Endereço4 Oppenheimer Street
CidadeREHOVOT
Bolsa de valoresNASDAQ OMX - NASDAQ BASIC
PaísIsrael
Código postal7670104
Telefone972732325600
Sitehttps://www.collplant.com
Código da empresaCLGN
Data de listagemSep 01, 1993
CEORotem (Eran)
Executivos da empresa Collplant Biotechnologies Ltd
Nome
Nome/Posição
Posição
Ações detidas
Variação
Mr. Yehiel Tal
Mr. Yehiel Tal
Chief Executive Officer
Chief Executive Officer
5.61K
+44.53%
Mr. Yehiel Tal
Mr. Yehiel Tal
Chief Executive Officer
Chief Executive Officer
5.61K
+44.53%
Mr. Yehiel Tal
Mr. Yehiel Tal
Chief Executive Officer
Chief Executive Officer
5.61K
+44.53%
Mr. Eran Rotem, CPA
Mr. Eran Rotem, CPA
Deputy Chief Executive Officer, Chief Financial Officer
Deputy Chief Executive Officer, Chief Financial Officer
2.63K
--
Mr. Eran Rotem, CPA
Mr. Eran Rotem, CPA
Deputy Chief Executive Officer, Chief Financial Officer
Deputy Chief Executive Officer, Chief Financial Officer
2.63K
--
Mr. Eran Rotem, CPA
Mr. Eran Rotem, CPA
Deputy Chief Executive Officer, Chief Financial Officer
Deputy Chief Executive Officer, Chief Financial Officer
2.63K
--
Dr. Philippe David Bensimon
Dr. Philippe David Bensimon
Vice President - Regulatory Affairs and Quality Assurance
Vice President - Regulatory Affairs and Quality Assurance
1.51K
+86.78%
Dr. Philippe David Bensimon
Dr. Philippe David Bensimon
Vice President - Regulatory Affairs and Quality Assurance
Vice President - Regulatory Affairs and Quality Assurance
1.51K
+86.78%
Dr. Philippe David Bensimon
Dr. Philippe David Bensimon
Vice President - Regulatory Affairs and Quality Assurance
Vice President - Regulatory Affairs and Quality Assurance
1.51K
+86.78%
Dr. Abraham (Avri) Havron, Ph.D.
Dr. Abraham (Avri) Havron, Ph.D.
Independent Director
Independent Director
313.00
--
Ver Mais
Nome
Nome/Posição
Posição
Ações detidas
Variação
Mr. Yehiel Tal
Mr. Yehiel Tal
Chief Executive Officer
Chief Executive Officer
5.61K
+44.53%
Mr. Yehiel Tal
Mr. Yehiel Tal
Chief Executive Officer
Chief Executive Officer
5.61K
+44.53%
Mr. Yehiel Tal
Mr. Yehiel Tal
Chief Executive Officer
Chief Executive Officer
5.61K
+44.53%
Mr. Eran Rotem, CPA
Mr. Eran Rotem, CPA
Deputy Chief Executive Officer, Chief Financial Officer
Deputy Chief Executive Officer, Chief Financial Officer
2.63K
--
Mr. Eran Rotem, CPA
Mr. Eran Rotem, CPA
Deputy Chief Executive Officer, Chief Financial Officer
Deputy Chief Executive Officer, Chief Financial Officer
2.63K
--
Mr. Eran Rotem, CPA
Mr. Eran Rotem, CPA
Deputy Chief Executive Officer, Chief Financial Officer
Deputy Chief Executive Officer, Chief Financial Officer
2.63K
--
Perguntas frequentes
Quem são os cinco principais acionistas de Collplant Biotechnologies Ltd?
Os cinco principais acionistas de Collplant Biotechnologies Ltd são: Mr. Yehiel Tal
Quantas instituições possuem ações da Collplant Biotechnologies Ltd (CLGN)?
Em 2026Q1, 35 instituições possuíam ações da Collplant Biotechnologies Ltd, com valor de mercado aproximado de 1.89M, representando 13.14% do total de ações. Em comparação com 2025Q4, a participação institucional aumentou em -218892.00.
Qual é a maior fonte de receita da Collplant Biotechnologies Ltd?
Em 2026Q1, o segmento de negócios Revenues from licensing agreement gerou a maior receita para Collplant Biotechnologies Ltd, totalizando 2.00M e representando 84.35% da receita total.